6.4.5.1.1. salvage radiotherapy psa-only recurrence radical prostatectomy (ctxcn0m0, withoutpet/ct). early srt provides possibility cure patients increasing psa rp. boorjian et al., reported 75% reduced risk systemic progression srt comparing 856 srt patients 1,801 non-srt patients . raves radical trials assessing srt post-rp patients psa levels exceeding 0.1–0.2 ng/ml showed 5-year freedom bcr bcr-free survival rates 88% . tilki et al. demonstrated results matched pair analysis 1832 patients bcr, 32.9% (n = 603) received srt without adt, 1229 (67,1%) observational strategy. median follow-up 95.9 months. median total srt dose 70.2 gy. 1:1 propensity score matching, fiveteen years rp, mfs os rates 84.3 versus 76.9% (p < 0.001) 85.3 versus 74.4% (p = 0.04) srt nort, respectively . psa level bcr shown prognostic . 60% patients treated psa level rises > 0.5 ng/ml achieve undetectable psa level [956-958], corresponding ~80% chance progression-free five years later . retrospective analysis 635 patients followed rp experienced bcr and/or local recurrence either received salvage treatment (n = 397) srt alone (n = 160) within two years bcr showed srt associated 3-fold increase pca-specific survival relative received salvage treatment (p < 0.001). salvage rt shown effective mainly patients short psa-dt . retrospective multi-centre study including 25,551 patients one high-risk factor rp (isup grade group 4-5 pt3/4), initiating srt psa level 0.25 ng/ml associated increased acm-risk. median follow-up six years, patients received srt psa level >0.25 ng/ml significantly higher acm-risk (ahr, 1.49; 95% ci, 1.11 2.00; p =.008) compared men received srt psa ≤0.25 mg/ml . overview srt see table 6.4.3. eau bcr definitions externally validated may helpful individualised treatment decisions . despite indication salvage rt, ‘wait see‘ strategy remains option eau bcr ‘low-risk’ group . although biochemical progression widely accepted surrogate marker pca recurrence; metastatic disease, disease-specific os meaningful endpoints support clinical decision-making. sr meta-analysis impact bcr rp reports srt favourable os pcsm. particular srt initiated patients rapid psa kinetics rp psa cut-off 0.4 ng/ml . international multi-institutional analysis pooled data rcts suggested mfs valid surrogate endpoint respect impact os . table 6.4.4 summarises results recent studies clinical endpoints srt. table 6.4.3: selected studies post-prostatectomy salvage radiotherapy, stratified pre-salvage radiotherapy psa level* (ctxcn0m0, without pet/ct) studynmedian fu (mo)pre-srt psa (ng/ml) medianrt doseadtbned/pfs (year)5-yr. resultsbartkowiak, et al. 2018 464710.3166.6 gy54% (5.9)73% vs. 56%; psa< 0.2 vs. > 0.2 ng/mlp < 0.0001stish, et al.2016 1,1061070.668 gy16% adt50% (5)36% (10)44% vs. 58%; psa< 0.5 vs. > 0.5 ng/mlp < 0.001tendulkar,et al. 2016 2,460600.566 gy16% adt56% (5)pre-srt psa71% 0.01–0.2 ng/ml63% 0.21–0.5 ng/ml54% 0.51–1.0 ng/ml43% 1.01–2.0 ng/ml37% > 2.0 ng/mlp < 0.001tilki et al. 2023 25,551srt at:psa <0.25n=1,556psa>0.25n=1.677no rt: n=21,64572not givenmed.68.4 gysrt+adt:1489art:n= 673adt: 208not givenacm (six years): hr 1.49 higher risk srt start >0.25(p=0.008) *androgen deprivation therapy influence outcome ‘biochemically evidence disease (bned)’ ‘progression-free survival’. facilitate comparisons, 5-year bned/pfs read-outs kaplan-meier plots included.adt = androgen deprivation therapy; bned = biochemically evidence disease; fu = follow up; mo = months; n = number patients; pfs = progression-free survival; psa = prostate-specific antigen; srt = salvage radiotherapy; yr = year. table 6.4.4: selected studies reporting clinical endpoints srt (ctxcn0m0, without pet/ct)(the majority included patients receive adt) studynmedian fu (mo)regimenoutcomebartkowiak, et al. 2018 4647166.6 (59.4-72) gy adt5.9 yr. ospost-srt psa < 0.1 ng/ml 98%post-srt psa > 0.1 ng/ml 92%p = 0.005jackson,et al. 2014 4486468.4 gy adt5 yr. dmpost-srt psa < 0.1 ng/ml 5%post-srt psa > 0.1 ng/ml 29%p < 0.00015 yr. dsmpost-srt psa < 0.1 ng/ml 2%post-srt psa > 0.1 ng/ml 7%p < 0.0001ospost-srt psa < 0.1 ng/ml 97%post-srt psa > 0.1 ng/ml 90%p < 0.0001stish,et al. 2016 1,10610768 (64.8-70.2) gy 39% 2d treatment planningincl. 16% adt5 8.9 yr. dmsrt: psa < 0.5 ng/ml 7% 12%srt: psa > 0.5 ng/ml 14% 23%p < 0.0015 8.9 yr. dsmsrt: psa < 0.5 ng/ml < 1% 6%srt: psa > 0.5 ng/ml 5% 10%p = 0.02 5 8.9 yr. ossrt: psa < 0.5 ng/ml 94% 86%srt: psa > 0.5 ng/ml 91% 78%p = 0.14tendulkar,et al. 2016 2,4606066 (64.8-68.4) gy incl. 16% adt10-yr. dm (19% patients)pre-srt psa9% 0.01–0.2 ng/ml15% 0.21–0.5 ng/ml19% 0.51–1.0 ng/ml20% 1.01–2.0 ng/ml37% > 2.0 ng/mlp < 0.001 adt = androgen deprivation therapy; dm = distant metastasis; dsm = disease specific mortality; fu = follow up; mo. = month; n = number patients; os = overall survival; psa = prostate specific antigen; srt = salvage radiotherapy.